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Abstract
PV1 protein is an essential component of stomatal and fenestral diaphragms, which are formed at the plasma membrane of
endothelial cells (ECs), on structures such as caveolae, fenestrae and transendothelial channels. Knockout of PV1 in mice
results in in utero and perinatal mortality. To be able to interpret the complex PV1 knockout phenotype, it is critical to
determine whether the formation of diaphragms is the only cellular role of PV1. We addressed this question by measuring
the effect of complete and partial removal of structures capable of forming diaphragms on PV1 protein level. Removal of
caveolae in mice by knocking out caveolin-1 or cavin-1 resulted in a dramatic reduction of PV1 protein level in lungs but not
kidneys. The magnitude of PV1 reduction correlated with the abundance of structures capable of forming diaphragms in the
microvasculature of these organs. The absence of caveolae in the lung ECs did not affect the transcription or translation of
PV1, but it caused a sharp increase in PV1 protein internalization rate via a clathrin- and dynamin-independent pathway
followed by degradation in lysosomes. Thus, PV1 is retained on the cell surface of ECs by structures capable of forming
diaphragms, but undergoes rapid internalization and degradation in the absence of these structures, suggesting that
formation of diaphragms is the only role of PV1.
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Introduction
Caveolae, fenestrae and transendothelial channels (TEC) are
endothelial structures involved in microvascular permeability
[1,2,3,4,5]. In the ECs of capillaries of visceral organs, these
structures are provided with diaphragms [1,6,7]. The only known
structural component of the diaphragms is PV1 [8,9,10,11,12], a
vertebrate protein encoded by the Plvap gene [1,11,13]. Knock-
down of PV1 in ECs in culture results in the disappearance of all
diaphragms [10,11,12]. Knockout of PV1 in mice also causes the
disappearance of all diaphragms and results in in utero and
perinatal mortality due to impairment of vascular permeability
[14].
Our understanding of the complex phenotype occurring in
PV12/2 mice would be strengthened by the knowledge of
whether the diaphragm formation is the only cellular role played
by PV1. We addressed this question by measuring the effect of
removal of endothelial structures capable of forming diaphragms
on the cellular PV1 protein level. PV1 and the diaphragms are
present only in ECs of microvessels (i.e. capillaries and venules) of
visceral organs. For the in situ approach, our analysis was focused
on microvessels in two types of vascular beds such as the lung and
the kidney. Lung capillaries are of a continuous type and their ECs
have only caveolae but no fenestrae or TEC [1]. Conversely,
kidney capillaries are of a fenestrated type, their ECs being
provided with fenestrae and TEC in great excess to caveolae
[1,15].
We showed that deletion of caveolae by knockout of their
components Cav1 [16,17,18] or PTRF/cavin-1 [19,20] resulted in
the dramatic decrease of PV1 protein level in lung microvascular
ECs, which lacked any structures capable of forming diaphragms.
We determined that the reduction in PV1 protein level was due to
increased internalization rate via a clathrin- and dynamin-
independent pathway followed by degradation in lysosomes. In
contrast to lungs, the absence of caveolae caused only slight
reduction in PV1 protein level in fenestrae- and TECs-rich
microvascular ECs of kidneys. Therefore, PV1 is retained on the
surface of microvascular ECs by structures capable of forming
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32655diaphragms. In the absence of these structures, PV1 undergoes
rapid internalization and degradation suggesting that formation of
diaphragms is the only function of PV1 protein.
Results
Protein level of PV1 is maintained by the presence of
structures capable of forming diaphragms in vivo
Knockout of Cav1 in mice (Cav12/2) led to the decrease
(84.4%+/27%) inPV1 proteinlevelinthe lungs(Fig.1A),inaccord
with a previous report [21]. This decrease was not due to a lower
number of ECs in Cav12/2, as indicated by similar protein levels
of endothelial marker CD31/PECAM-1 [22,23] in Cav12/2,
Cav+/2 and WT (Fig. 1A). A similar reduction (76.6+/211%) in
PV1 protein level in the lungs was observed for knockouts of cavin-1
(cavin-12/2)(Fig.1B).Incontrasttolungs,theremovalofcaveolae
in kidneys by knockout of Cav1 caused only a slight reduction
(17.5%+/23) in protein level of PV1 (Fig. 1C). PV1 mRNA levels
in lungs and kidneys were similar among WT, Cav12/2 and
cavin-12/2 mice (Fig. 1D), indicating that transcription of PV1
is not affected by the lack of caveolae.
We employed transmission electron microscopy (TEM) to get a
better understanding of structural differences between the
microvasculature of lungs and kidneys in the context of diaphragm
formation. In concordance with previous studies [8,9,24,25]
(reviewed in [1]), ECs in lungs of WT formed caveolae provided
with diaphragms but did not form fenestrae or TEC (Fig. 2A, left
lower panels). The removal of caveolae by knockout of either Cav1
or cavin-1 resulted in lung microvasculature completely devoid of
all structures capable of forming diaphragms (Fig. 2A, middle and
right lower panels). In contrast to the lungs, ECs in the peritubullar
capillaries of kidneys contained many fenestrae and TEC provided
with diaphragms [15] (Fig. 2A, left upper panel). Removal of
caveolae did not affect the ability of ECs in kidney peritubullar
capillaries to form these structures (Fig. 2A, middle and right upper
panels). Morphometric analysis confirmed on one hand the absence
of caveolae in the microvasculature of Cav12/2 lungs (Fig. 2B)
and kidneys (Fig. 2C), and on the other hand it showed that the
densities of fenestrae and TEC in the kidneys of Cav12/2 and
WT mice were similar (Fig. 2C). Thus, removal of caveolae caused
a complete absence of structures capable of forming diaphragms
and low PV1 protein level in the microvasculature of the lungs. In
contrast, the microvasculature of the kidneys of Cav12/2 mice
had high numbers of structures capable of forming diaphragms
(fenestrae and TEC) and high PV1 protein level.
Protein level of PV1 is maintained by the presence of
caveolae in vitro
To investigate the mechanism by which structures capable of
forming diaphragms maintain PV1 protein level, we employed
mouse lung endothelial cells (MLECs) which, when isolated from
WT (WT) mice, form caveolae but not fenestrae or TEC [26,27].
Caveolae do not form in MLECs isolated from Cav12/2 mice
(Cav1KO), but form in MLECs isolated from Cav12/2 mice in
which Cav1 expression was reconstituted with transgenic expres-
sion of canine Cav1 under the control of the endothelial-specific
preproendothelin promoter (Cav1ECRC) [26,27]. The amount of
PV1 protein translated and matured to fully N-glycosylated form
in MLEC-Cav1-ECRC was similar to that in the MLEC-WT and
higher than in MLEC-Cav1KO (Fig. 3A). Therefore, the PV1
protein level in MLEC in vitro is maintained by the presence of
caveolae.
The direct correlation between the presence of caveolae and
PV1 protein level in lung ECs suggests that PV1 predominantly
associates with caveolae on the cell surface of MLEC-WT. We
examined the specificity of PV1 association with caveolae in
MLEC-WT using two-color total internal reflection fluorescent
microscopy (TIRFM). TIRFM allowed us to visualize the
fluorescent signal only in the coverglass-proximal region of the
cell (<100 nm calculated penetration angle) mostly corresponding
to plasma membrane. Live MLEC-WT expressing Cav1-GFP
were labeled at 4uC with fluorophore tagged anti-PV1 antibodies
and imaged at 37uC immediately thereafter. PV1 predominantly
associated with caveolae as indicated by extensive co-localization
of PV1 with Cav1-GFP (white arrows, Fig. 3B).
Absence of caveolae does not affect the transcription
and translation rates of PV1
Reduction in total PV1 protein levels in ECs lacking caveolae
could be explained by defects in transcription or translation of
PV1. We examined this possibility by determining the effect of
Cav1 knockout on PV1 mRNA level and translation rate of PV1
protein in lung ECs isolated from wild type (MLEC-WT) and
Cav12/2 (MLEC-Cav1KO) mice. The level of PV1 mRNA
Figure 1. Protein level of PV1 is maintained by the presence of
caveolae in vivo. A–B) Protein levels of PV1, Cav1 and CD31 in the
lung (A) and kidney (B) total membranes of Cav12/2, Cav1+/2 and WT
mice were detected by immunoblotting. C) Protein levels of PV1, cavin-
1 and CD31 in the lung total membranes of cavin-12/2 and WT mice
were detected by immunoblotting. D) PV1 mRNA levels in the lung (left
panel) and kidney (right panel) of WT, Cav12/2 and cavin-12/2 mice.
doi:10.1371/journal.pone.0032655.g001
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MLEC-Cav1KO (Fig. 4A), in agreement with in vivo data (Fig. 1D).
Thus, deletion of Cav1 does not affect PV1 mRNA level in ECs.
The translation rates of PV1 mRNA into protein were measured
by pulse metabolic labeling of MLEC-WT and MLEC-Cav1KO
cells with
35S-methionine and
35S-cysteine. Immunoprecipitated
and SDS-PAGE resolved
35S-labeled PV1 appeared as five bands
by fluorography, representing the non-glycosylated, N-glycosylation
intermediates and fully N-glycosylated forms of PV1 polypeptide.
PV1 has four functional N-glycosylation sites [8] that were
confirmed by point mutagenesis (D. Tse, R. Stan, manuscript in
preparation).TheamountofPV1 proteintranslatedand maturedto
fully N-glycosylated form in the MLEC-Cav1KO was similar to the
WT cells (Fig. 4B–C), demonstrating that Cav1 absence has no
effect on the translation rate of PV1 in lung ECs.
PV1 is retained on the surface of lung endothelial cells by
caveolae
We hypothesized that the low PV1 protein level in lung ECs
lacking caveolae may be explained by PV1 rapid internalization
and degradation due to the absence of structures that can form
diaphragms and retain PV1 on cell surface. We examined
internalization rates of PV1 from the surface of MLEC-Cav1KO
and MLEC-WT by flow cytometry (Fig. 5A). In accord with our
hypothesis, the amount of PV1 on the surface of MLEC-Cav1KO
was much lower than in MLEC-WT (Fig. 5B). PV1 was
internalized in time-dependent manner (Fig. 5C) but the rate of
PV1 internalization was significantly higher in MLEC-Cav1KO
than in MLEC-WT (Fig. 5D–E). Therefore, absence of Cav1, a
critical structural component of caveolae, resulted in an acceler-
ated rate of PV1 internalization from the surface of lung ECs.
Figure 2. Protein level of PV1 correlates with the number of structures capable of forming diaphragms in vivo. A) Electron micrographs
of capillary ECs of the kidneys (top panels) and lungs (middle and bottom panels) of WT, Cav12/2 and cavin-12/2 mice, as indicated. TEC and
fenestrae are present in the kidneys of WT, Cav12/2 and cavin-12/2 mice (top panels). (Middle and bottom panels) Caveolae with stomatal
diaphragms are present in the lungs of WT and absent in Cav12/2 and cavin-12/2 mice (middle panel). Insets in middle panels are a 2-fold
magnification of the noted stretches of ECs. Bottom panels are a 3-fold magnification of ECs of Cav12/2 (left) and cavin-12/2 (right). Bars 2200 nm.
B) Morphometric analysis of the number of lung endothelial caveolae in WT and Cav12/2 mice demonstrating the absence of caveolae in the latter.
C) Morphometric analysis of the numbers of kidney endothelial TEC, fenestrae and caveolae in WT and Cav12/2 mice.
doi:10.1371/journal.pone.0032655.g002
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Cav1KO and MLEC-WT by using
35S metabolic labeling. The
cells were pulsed with
35S-methionine and
35S-cysteine and a chase
for 1, 4, 8 and 24 h allowed us to determine the half-life (t1/2)o f
35S-labeled PV1 protein. In MLEC-Cav1KO cells, total cellular
PV1 t1/2 was in the range of ,4 h, significantly shorter than in
MLEC-WT (Fig. 5F). Therefore, the absence of caveolae in lung
microvascular ECs resulted in a higher rate of degradation of the
fully glycosylated PV1 protein.
To determine the mechanism of PV1 degradation we treated
MLEC-WT and MLEC-Cav1KO with pharmacological inhibi-
tors of either lysosomal or proteasomal degradation. Lysosomal
enzymes were inhibited by treatment with 1 or 10 mM
bafilomycin A1 (a V-ATPase inhibitor and inhibitor of lysosomal
acidification [28]), 50 mM leupeptin (a serine and cysteine
protease inhibitor) [29] or 10 mM E-64D (a membrane
permeable cysteine protease inhibitor) [30] for 24 h and
determination of PV1 levels by western blotting. Each of these
inhibitors increased total cellular PV1 protein levels at 24 h
(Fig. 5G). Inhibition of PV1 degradation had greater effect on
protein level of PV1 in MLEC-Cav1KO than in MLEC-WT in
agreement with an increased degradation rate of PV1 in the
former cells. Inhibitors of the proteasomal pathway such as 2 mM
epoxomycin [31] and 10 mM clasto-lactacystin b-lactone [32] had
no effect on PV1 levels after 4, 8 or 24 h treatment (Fig. 5G–H
and data not shown). Therefore, PV1 in MLECs is degraded in
lysosomes.
PV1 is internalized in clathrin- and dynamin-
independent manner
We examined the mechanism of PV1 internalization by
studying its dependence on clathrin and dynamin, molecules with
essential roles in several endocytosis pathways [33,34,35]. PV1 on
plasma membrane did not colocalize with clathrin light chain at
the cell surface of WT cells (Fig. 6A). Unsurprisingly, treatment of
cells with PitStop2, a cell-permeant amphiphilic inhibitor of
clathrin-mediated uptake (CME), did not have a statistically
significant effect on the amount of internalized PV1 at 15 and
60 min time points in WT and Cav12/2 cells (Fig. 6B), while
inhibiting the uptake of transferrin that is known to undergo
Figure 3. Protein level of PV1 is maintained by the presence of
caveolae in vitro. A) Protein levels of PV1 in MLEC-wt(WT), MLEC-
Cav1KO (Cav1KO) and MLEC-Cav1-ECRC (ECRC) cells detected by
immunoblotting with anti-PV1 antibodies. M -C o r r e s p o n d st o
membrane proteins, C – cytosolic proteins. Equal amount of membrane
protein was loaded whereas the cytosolic proteins were normalized to
membrane extract volume. The membrane and cytosolic proteins were
also partially deglycosylated with PNGase F (+), which resulted in the
drop in PV1 molecular weight. Note very low PV1 level in Cav1KO cells
and increased PV1 protein level in cells reconstituted with Cav1 (Cav1-
ECRC). The top and bottom panels are different exposures of the same
blot. B) PV1 is predominantly associated with caveolae on the surface of
lung endothelial cells. PV1 (red) colocalizes with Cav1-EGFP (green)a t
the plasma membrane of live MLEC, as shown by TIRFM. Insets
demonstrate the extensive colocalization of the two labels (white
arrowheads). Scale bars 220 mm.
doi:10.1371/journal.pone.0032655.g003
Figure 4. Absence of caveolae in lung ECs does not affect
transcription and translation levels of PV1. A) PV1 mRNA levels in
MLEC-wt (WT) and MLEC-Cav1KO (Cav1KO) cells measured by real time
quantitative PCR. The data was obtained from quadruplicate samples
and normalized to b-actin mRNA levels (DDCt). Bars – SEM. B) Pulse
35S
metabolic labeling of MLEC-WT (top panel) and MLEC-Cav1KO (bottom
panel) cells followed by PV1 immunoprecipitation at the indicated time
points and
35S fluorography. Duplicate samples are shown for each time
point assessed. PV1 has four active N-glycosylation sites and therefore
shows five bands, the lowest representing the non-glycosylated form
and the four higher bands representing various degrees of N-
glycosylation. C) Densitometric quantitation of the amount of PV1
translated after 10 min pulse with
35S-methionine and cysteine in
MLEC-WT and MLEC-Cav1KO cells. Error bars correspond to SEM (n=3).
doi:10.1371/journal.pone.0032655.g004
In Absence of the Diaphragms PV1 is Degraded
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32655internalization in clathrin coated vesicles (Fig. 6E) [36,37].
Treatment with inhibitors of dynamin Dyngo4a [36] (Fig. 6C)
or Dynasore [38] (Fig. 6D) had no effect on PV1 internalization
while inhibiting the internalization of transferrin (Fig. 6E).
Similarly, inhibition of dynamin by overexpression of dynamin
2(K44A)-EGFP construct encoding a dominant negative form of
Figure 5. PV1 is retained on the surface of lung endothelial cells by caveolae. A) Schematic of the timeline (upper right) and the principal
steps of PV1 internalization flow cytometric assay (right). An example of data gating and fluorescence intensity histogram is given in the lower left
panels. B) Amount of PV1 on the surface of MLEC-wt (WT) and MLEC-Cav1KO (Cav1 KO) at t0 expressed as median fluorescence intensity per cell from
fluorophore-labeled anti-PV1 (PV1). Labeling of cells with isotype control non-immune antibodies showed the level of unspecific binding (control)
(error bars correspond to stdev, n=4, *p,0.01). C) Amount of internalized PV1 at different time points in MLEC-WT at 37uC( solid line) and 4uC( dashed
line) expressed as median fluorescence intensity per cell from fluorophore-labeled anti-PV1 (PV1) (stdev, n=6, *p,0.01). D) PV1 internalization in
MLEC-WT (WT, top panels) and MLEC-Cav1KO (Cav1 KO, bottom panels) cells at different time points, as detected by confocal microscopy. Images are
maximum projections of confocal stacks in green channel (PV1, lower panels) or green merged with blue (nuclei labeled with DAPI, upper panels). E)
Internalization rate of PV1 in MLEC-WT (solid line, solid circles) and Cav1KO (dashed line, open circles) cells, expressed as a percentage from the total
amount of PV1 on the cell surface. (stdev, n=4 per time point, *p,0.01). F) Degradation curves of
35S labeled PV1 in MLEC-Cav1KO (Cav1KO, dashed
line, open circles) and MLEC-WT (WT, solid circles), isolated from Cav12/2 and wild type mice, respectively. Data is representative of three experiments
carried out in duplicate. G, H) PV1 degradation rates were measured in MLEC-WT (WT) and MLEC-Cav1KO (Cav1KO) treated with lysosomal or
proteasomal inhibitors. G) Western blots used for densitometric quantifications of PV1 protein level. H) Quantitation of protein levels of PV1.
doi:10.1371/journal.pone.0032655.g005
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60 min (Fig. 6F), while inhibiting the uptake of transferrin
(Fig. 6G). Thus, PV1 is internalized via a clathrin- and
dynamin-independent pathway.
Discussion
PV1 is an essential component of endothelial diaphragms and a
molecule critical for postnatal survival of mice. A major
unanswered question in the interpretation of the dramatic
phenotype of PV12/2 mice is whether the absence of
diaphragms is the only function of PV1. Here, we addressed this
question by combining in vivo and in vitro approaches in which we
looked at PV1 retention on the plasma membrane in the presence
and absence of structures capable of forming diaphragms on the
surface of endothelial cells. We found that, in the absence of
structures capable of forming diaphragms, PV1 protein is
transported to the cell surface followed by rapid internalization
and degradation. In our model (Fig. 6H), PV1 is delivered via the
secretory pathway to the plasma membrane where PV1 is
incorporated into the diaphragms formed on subcellular structures
such as caveolae, fenestrae and TEC. PV1 molecules, which are
not part of the diaphragms, are rapidly internalized by a clathrin-
and dynamin-independent pathway and degraded into lysosomes.
In summary, our results strongly suggest that the only role of PV1
is to form diaphragms on the cell surface.
The magnitude of PV1 protein level reduction as a result of
caveolae removal was different in the lungs and kidneys. The
observation of reduced lung PV1 protein level was in accord to a
previous report [21]. The reduced PV1 protein level in the lung
microvascular ECs of Cav12/2 mice could not differentiate the
roles of Cav1 and/or caveolae in regulation of cellular PV1
amounts. To define whether the reduced PV1 protein level was
due to the absence of Cav1 per se or to the absence of caveolae, we
analyzed another mouse model in which caveolae do not form,
namely cavin-12/2 mice. In cavin-12/2 mice Cav1 is still
expressed and transported to the plasma membrane but it does not
induce caveolae formation and is rapidly internalized and
degraded [19,40]. PV1 protein level in lung ECs of cavin 12/2
was reduced as compared to WT demonstrating that PV1
expression is down regulated by the absence of caveolae. In
contrast to the lungs, PV1 protein level in kidneys was only slightly
reduced in Cav12/2 compared to WT consistent with the fact
that caveolae represent only a minority of the structures capable of
forming diaphragms in the kidney microvascular ECs. TEM
analysis of the Cav12/2 kidney demonstrated that the numbers
of fenestrae and TEC are unchanged from WT, whereas caveolae
were absent. Thus, the drop in PV1 protein level in different
organs as a result of Cav1 knockout correlated with the level of
reduction in the number of structures capable of forming
diaphragms.
To gain insight into the mechanism responsible for PV1
decrease as a result of caveolae removal, we have employed an in
vitro system of cultured lung microvascular ECs isolated from
Cav12/2, Cav1-ECRC and WT mice. As shown before [27], the
WT lung microvascular ECs have only caveolae and no fenestrae
and TEC. Similar to in situ, the lack of caveolae in Cav1KO-
MLEC correlates with low total cellular PV1 level. Thus, our data
show, both in situ and in vitro, that the absence of structures capable
of forming diaphragms leads to a decrease of PV1 protein level.
The low PV1 protein level in absence of caveolae could be due
to decreased production, increased degradation rate or a
combination of the two. Our data showed that the decrease in
PV1 protein level was not due to diminished PV1 transcription
(both in situ and in culture) or translation rates, which are similar in
WT and Cav12/2 ECs in culture. Moreover the N-glycosylation
rate of PV1 is similar in WT and Cav12/2 MLECs,
demonstrating similar progression through the secretory pathway
components such as the endoplasmic reticulum and the Golgi
complex, where the N-glycosylation is completed and from where
PV1 is delivered to the cell surface. Our data in the kidney
capillary ECs in situ and in MLECs show that PV1 does not
require caveolae or Cav1 in order to be delivered to the cell
surface. Previous surface biotinylation experiments showed that
most (.95%) of the cellular PV1 in ECs occurs at the cell surface,
all of it in its fully N-glycosylated form [11]. Similarly, in our
experiments PV1 is delivered to the cell surface and .95% of PV1
is fully N-glycosylated in both WT and Cav12/2 ECs (and
Cav1ECRC). Thus, the production and trafficking of PV1 protein
to the cell surface do not seem to be affected by the absence of
caveolae and as such are not the cause of the decrease in PV1
protein levels. Still PV1 protein level on plasma membrane of
Cav12/2 ECs is significantly lower as compared to WT. This is
not due to proteolysis and shedding but rather to an accelerated
rate of internalization followed by degradation, as shown by pulse
metabolic labeling and experiments using lysosomal degradation
inhibitors. Altogether, these data argue that while PV1 arrives at
the plasma membrane in normal fashion, it is not retained on the
cell surface in the absence of structures capable of forming
diaphragms (i.e. caveolae) being internalized and targeted toward
lysosomal degradation.
Our in situ experiments strongly suggest a role for fenestrae and
TEC similar to caveolae in retaining PV1 at the plasma
membrane. Technical limitations do not allow us to use cell
culture methods to confirm the role of fenestrae and TEC in
retention of PV1 on the cell surface. Induction of fenestrae and
TEC can be achieved by treatments with phorbol esthers [11] and
VEGF [12,41] but these treatments also cause an increase PV1
mRNA transcription. Other methods using actin cytoskeleton
disruptors [12] perturb many cellular functions aside from
endocytosis. Therefore, we can rely only on our in situ data to
draw conclusions on the role of fenestrae and TEC in retention of
PV1 at the plasma membrane.
The internalization of PV1 occurs via a clathrin- and dynamin-
independent pathway in both WT and Cav12/2 lung ECs.
These criteria exclude clathrin-mediated uptake and also exclude
the dynamin-sensitive clathrin-independent pathways such as
caveolae [42,43,44], the RhoA controlled IL-2R pathway [45]
and the growth factor induced macropinocytosis [46]. Similar
dynamin-insensitive non-clathrin endocytic pathways have been
already described such as the CLIC pathway [47], the pathway for
syndecan 4 internalization in ECs [48], the pathway induced by
multivalent toxins and SV40 virus [49,50] and the pathway for
CD36 and oxidized low density lipoprotein particles [51], to name
a few. Our data suggest that to enter ECs, PV1 needs to dissociate
from caveolae following some form of signal or following to
caveolae disassembly. Finally, the faster rate of PV1 internalization
in the Cav12/2 ECs suggests that: i) Cav1/caveolae have a
direct inhibitory effect on the PV1 uptake pathway in WT ECs, or
ii) PV1 uptake acts in constitutive manner and the rate of
dissociation of PV1 from caveolae controls the rate of its
internalization. PV1 is internalized via a pathway that feeds into
the endolysosomal system leading to its degradation in the
lysosomes. Further work will elucidate the details of PV1
internalization and trafficking.
In summary, we found that PV1 is faithfully associated with the
diaphragms formed in the neck of caveolae, fenestrae and TEC. In
the absence of the structures capable of forming the diaphragms,
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32655Figure 6. PV1 is internalized in clathrin and dynamin independent manner in WT and Cav12/2 cells. A) PV1 does not colocalize with
clathrin-GFP on the cell surface. Confocal micrographs of MLEC-WT transfected with clathrin-GFP (Clathrin, green) and labeled with fluorescent anti-
PV1 antibodies (PV1, red). The insets represent a low power field with two transfected cells. The areas in shaded in grey are magnified in lowed panels.
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32655PV1 undergoes rapid internalization and degradation. These
findings will prove to be important in future investigations on the
cause of metabolic defects observed in PV1 knockout mice [14] as
well as on the significance of PV1 upregulation observed during
angiogenesis [41,52] and inflammation [53,54] (reviewed in [1,7]).
Materials and Methods
Materials
Cell culture regents were from Lonza (Walkersville, MD).
Pharmacological inhibitors bafilomycin A1 (from Streptomyces
griseus), Dynasore (3-Hydroxynaphthalene-2-carboxylic acid-(3,4-
dihydroxybenzylidene)-hydrazide), E-64D ((2S,3S)-trans-Epoxysuc-
cinyl-L-leucylamido-3-methylbutane Ethyl Ester) and leupeptin
were from EMD Biosciences/Merck (San Diego, CA), Dyngo 4a,
PitStop2 and PitStop2 negative control were from Ascent
Scientific/Abcam (Princeton, NJ), whereas epoxomycin and
clasto-Lactacystin b-Lactone were from Boston Scientific (Natick,
MA).
Mice
Caveolin 12/2 (Cav12/2) mice on C57Bl/6 background
(strain B6.Cg-Cav1
tm1Mls/J) [55] were obtained from The Jackson
Laboratory (Bar Harbor, Maine). The mice were maintained by
heterozygous (Cav1+/2) cross breeding to generate to generate
Cav12/2, Cav1+/2 and WT littermates. Every 5 generations
Cav12/2 mice were bred to C57Bl/6J mice from Jackson
Laboratory. Cavin-12/2 mice on C57Bl/6 background were
from Dr. P. Pilch, Boston University [20].
Cells
Mouse polyoma virus middle T antigen immortalized mouse
lung ECs (MLEC) obtained from Cav1KO (MLEC-Cav1KO),
Cav1 ECRC (MLEC-Cav1 ECRC) and WT (MLEC-WT) mice,
as described [27,56,57,58]. The cells were flow sorted for surface
expression of both CD31 and PV1 using a FACSAria sorter (BD
Biosciences), as described below. All mouse lung ECs were
cultured on plastic in MLEC growth medium consisting of
endothelial growth medium 2 (EGM2) (Lonza, Walkersville, MD)
supplemented with 15% heat inactivated fetal bovine serum
(Hyclone), 100 mg/ml penicillin, 100 mg/ml streptomycin and
100 mg/ml glutamine (Invitrogen, Carlsbad, CA). HUVEC were
obtained from Lonza and were cultured in EGM2 medium. The
hybridoma secreting the rat anti-mouse PV1 IgG2a mAb MECA-
32 [6,59] were from the Developmental Studies Hybridoma Bank,
University of Iowa.
Antibodies
Rabbit anti caveolin 1 pAb (cat# 610060) and mouse anti –
PTRF (cavin1) mAb, clone #4 (Cat# 611259) were purchased
from BD Bioscience (San Diego, CA). Rat anti-mouse CD31
(PECAM-1) clone MEC13.3 – APC (Cat# 102510) was from
BioLegend. Mouse anti-beta-actin mAb (AC40) was from Sigma
(St.Louis, MO). Rabbit anti ERK1/2 mAb was from Cell
Signaling (Beverly, MA). Goat anti-CD31 (PECAM-1) pAb (M-
20, cat# sc-1506) and goat anti-Cdh5 (VE Cadherin, CD146) pAb
(C-19, cat# sc-6458) were from Santa Cruz. The unlabeled and
HRP-conjugated rabbit anti-chicken IgY and the goat anti-mouse
IgG-HRP were from Biodesign (Kennebunk, ME). Rat anti-mouse
PV1 IgG2a mAb, clone MECA-32 mAb was produced in serum
free media by BioXCell, Lebanon, NH. Chicken anti-mouse PV1C
pAb was raised in chickens against the last 12 aa of mouse PV1 C
terminus, as described in the past for chicken anti-human PV1C
pAb [8,11].
Primary antibody labeling with fluorophores
Affinity purified primary antibodies rat anti-mouse PV-1 mAb
clone MECA-32 and chicken anti-mouse PV-1C pAb, were
labeled with either Alexa (488, 568 or 647) fluorophores
(Molecular Probes, Invitrogen), as per manufacturer’s instructions.
Cell Sorting
MLEC-Cav1KO, MLEC-Cav1 ECRC and MLEC-WT cells
were cultured in 10 cm dishes to confluence. The cells were
incubated (30 min, 10uC) live with 1:500 anti-CD31-APC
(BioLegend) and anti-PV1-AF488 mAb clone MECA-32 (1 mg/
ml) diluted in MLEC growth medium. The excess antibody was
rinsed (365 ml) with sterile PBS (Invitrogen) and the cells
dissociated nonenzymatically with cell dissociation solution
(Sigma). The gating parameters were set on CD31+/PV1+
positive cells.
Electron microscopy
Specimen preparation for electron microscopy was done as
before [8,9]. Cav12/2 mice or WT littermates were perfused
(10 min, RT) under anesthesia, with oxygenated DMEM through
the left ventricle, followed by fixation by perfusion (10 min at RT)
with 2.5% glutaraldehyde and 3% paraformaldehyde in 0.1 M
sodium cacodylate buffer (pH 7.3). Specimens were taken from
different tissues and trimmed into small blocks. The blocks were
immersed into fresh fixative (1 h at RT), washed twice (15 min,
RT) in 0.1 M cacodylate, postfixed in Palade’s OsO4 (1 h on ice),
en bloc-stained in Kellemberger’s uranyl acetate (overnight at
RT), dehydrated in graded ethanol, and embedded in LX112
resin (Ladd Research Industries, Burlington, VT). Thin sections
(40 nm) with a Leica Ultracut (UC-6) using an ultrasonic
oscillating diamond knife (Diatome, US), stained with lead citrate,
and examined and photographed under an electron microscope
(JEOL 1010).
Morphometry
Morphometry was done as before [9,57] on lungs and kidneys
obtained from Cav12/2 and WT mice. The measurements were
obtained from capillaries found in 15–20 sections per animal per
B–G) PV1 and transferrin internalization rates in MLECs were quantified by flow cytometry. Error bars correspond to StDev. B–D) Percentage of
fluorescent antibody labeled PV1 internalized from the cell surface. B) PV1 internalization at 15 and 60 min in presence and absence of the clathrin
pathway inhibitor PitStop2 (PS2) or the inactive PitStop2 negative control (NC)( n=4 ,p.0.05). C,D) PV1 internalization at 15 and 60 min in presence
of dynamin inhibitors Dyngo-4a (C) (n=4, p.0.05) or Dynasore (D) (n=4, p.0.05). E) Median fluorescent intensity of transferrin-Alexa647 internalized
within 10 min in the presence and absence of PitStop2, Dynasore or Dyngo4a (n=4, *p,0.01). D–G) Internalization of PV1 (F) and transferrin (G) at
15 min in untransfected MLECs (mock) and MLECs transfected with eGFP-encoding plasmid (GFP), dynamin 2-eGFP fusion (Dyn2 wt) or dominant-
negative form of dynamin 2 fused to eGFP (Dyn2 K44A MLECs (n=4, *p,0.01). H) Schematic of PV1 (green) trafficking in ECs. De novo formed PV1
enters the secretory pathway and arrives at the cell surface by exocytosis (green arrow) using secretory vesicles (Step 1). On the plasma membrane
PV1 is targeted to caveolae, fenestrae or TEC (Step 2) where it forms diaphragms. PV1 is internalized via clathrin- and dynamin-independent endocytic
mechanism (Step 3 and 4) followed by degradation in the lysosomes (Step 5).
doi:10.1371/journal.pone.0032655.g006
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In the case of the lung, the number of caveolae per mmo fE C
length was determined by counting the number of uncoated
plasmalemma invaginations in the 50–100 nm size range [6] at the
luminal or abluminal front of the ECs in capillaries (i.e. blood
vessels with ,10 mm diameter) [1]. The total membrane length
examined was determined by summing the total length of luminal
membrane to the total length of abluminal membrane. The data
obtained in all animals per group was expressed as number of
caveolae per mm endothelial membrane length. Student’s t test was
used to determine statistical significance between WT and
Cav12/2 groups.
In the case of the kidney, we have determined the number of
caveolae, TEC and fenestrae per mm EC length in the ECs of the
peritubullar capillaries following the methodology previously
described by Millici, et al., [15]. By this, caveolae, TEC and
fenestrae were counted only in the areas in which EC thickness
was less than 400 nm, as these are the areas where TEC and
fenestrae occur. In the case of uncertainty as to whether a
transendothelial opening was a TEC (i.e. with two diaphragms) or
a fenestra (i.e. only one diaphragm) we have labeled this as an
unknown (U). The data is expressed as the total number of
structures found in 45–50 sections from each genotype divided by
the membrane length. Because the fenestrae and TEC involve
both fronts of the EC plasma membrane (i.e. luminal and
abluminal) we have considered the total membrane length as an
average of the luminal and abluminal plasma membrane.
Colocalization of PV1 and Cav1 by Total Internal
Reflection Fluorescence Microscopy (TIRFM)
MLEC-wt cells were seeded at 50% confluence on glass bottom
dishes (MatTek) and were trasnfected with Cav1-EGFP [48], using
Fugene 6 (Roche). Twenty four to forty eight hours post
transfection the cells were labeled live with 1.5 mg/ml MECA-
32-Alexa 568 mAb for 30 min at 4uC in MLEC growth medium,
the cells rinsed (36, RT) in MLEC growth medium and
immediately used for live TIRFM.
TIRFM images were acquired live as before [60], using an
Olympus IX71 inverted microscope equipped with a temperature-
controlled stage set at 32uC, a 1.45 NA 606 TIRFM lens
(Olympus), back-illuminated electron-multiplying charge-coupled
device camera (5126512, 16-bit; iXon887; Andor Technologies),
and controlled by Andor iQ software (Andor Technology).
Excitation was achieved using a 488-nm and a 514-nm line of
laser, and exposure times were 0.1–0.2 s and acquired at 0.5–
4 Hz. The calculated evanescent field depth was 100 nm.
Due to optical characteristics of the two wavelengths leading to
an uneven signal in the two wavelengths in TIRFM, the
colocalization was done by scoring puncta positive for the two
labels and not by the usual thresholding and calculation of the
colocalization index but manually.
Transfections
MLEC-WT were seeded at 70–90% confluence in 12 well plates
and transfected with different DNA constructs using Superfect
(Qiagen), as per manufacturer’s instructions. The DNA constructs
were as reported before [48]: EGFP-clathrin light chain from J.
Keen (Thomas Jefferson University, Philadelphia, PA) and
dynamin 2 wt-EGFP and dynamin 2(K44A)-EGFP in pEGFP-
N1 vector from M. McNiven [39] (Mayo Clinic, Rochester MN).
pEGFP-N1 empty vector was from Clontech. Forty-eight hours
post transfection the cells were labeled with fluorescent anti-PV1
and processed for either confocal microscopy or flow cytometry.
Confocal microscopy
MLEC were serum starved (2 h, 37uC, EBM2), labeled (30 min,
10uC, EBM2+1%BSA) with fluorescent anti-PV1 (5 mg/ml) and
rinsed (36, RT) in PBS containing calcium and magnesium (PBS-
CM) and chased (37uC, MLEC growth medium) for different
amounts of time. After 0, 15, 60 and 120 min the cells were rinsed
(2630 sec, RT) at low pH to facilitate detachment of non-
internalized antibodies, rinsed 16in neutral PBS, fixed (10 min,
RT) in 4% paraformaldehyde in PBS-CM, rinsed again in PBS-
CM containing DAPI, mounted in PermaFluor (Thermo Fisher)
mounting medium and examined by confocal fluorescence
microscopy using a Zeiss 510 Meta confocal system equipped
with a 636oil immersion objective and appropriate lasers. Stacks
of images were acquired with the pinhole set at 1 Airy unit and
processed using ImageJ software. For PV1 internalization, stacks
were transformed through the maximum intensity projection
function to obtain global images of the cells. Figures were prepared
using Adobe Photoshop and Adobe Illustrator CS3 software.
Isolation of total membranes from lungs and kidneys
Lung and kidney membrane lysates were obtained from WT,
Cav1
2/2, Cav1
+/2 and cavin-1
2/2 mice, as described in the past
[9]. The mice were anesthetized with a mixture of ketamine :
xylazine : acepromazine (3:1:0.25). The lungs and the kidneys
were immediately flushed free of blood by perfusion (10 min,
25uC) with oxygenated phenol-red free HBSS, via the pulmonary
artery or the left ventricle, respectively. The organs were freshly
collected, weighed, minced and homogenized (20 strokes, Teflon
pestle-glass Thomas type BB homogenizer) in an ice-cold buffer
(1:4/w:v) containing 25 mM Hepes, pH 7.2, 250 mM sucrose,
2 mM MgCl2 and a protease inhibitors cocktail (10 mg/ml each
leupeptin, pepstatin, o-phenantrolin, E-64 and 1 mM PMSF). The
homogenate was filtered through 53 mm nylon net and centrifuged
for 15 min at 5006g to yield a nuclei/cell debris pellet and a
postnuclear supernatant (PNS). The PNS was further fractionated
by centrifugation (1 h, 4uC, 100,0006g, using a TLA45 rotor) in a
total membranes pellet and a cytosolic supernatant. The
membrane pellet was solubilized in 200 ml 10 mM Tris, pH 6.8,
0.5%SDS, and protease inhibitors (Sigma). Protein concentration
was determined by a bicinchoninic acid method (Pierce, Rockford,
IL/USA) using BSA standards standards prepared in solubiliza-
tion buffer, as described previously [10,11]. Equal amounts of
protein (20 mg) were adjusted to 16reducing SDS-PAGE sample
buffer, boiled for 5 min, resolved by 12% or 8% SDS-PAGE,
transferred to PVDF membrane and probed by immunoblotting.
Antibodies used were either the rat anti-mouse PV1 MECA-32
mAb, the chicken anti-mouse PV1C pAb described here, rabbit
anti caveolin 1 pAb, mouse anti-Cavin-1/PTRF, goat anti CD31
pAb, goat anti-VE Cadherin pAb and rabbit anti-Cavin 2/SDPR
(Abcam). The lung membrane lysates were obtained from WT,
Cav1KO, Cav1
+/2 and Cavin-12/2 mice.
MLEC fractionation
CD31 and PV1 positive MLEC-WT, -Cav1KO or -Cav1-
ECRC grown to confluence in 2615 cm dishes were scrapped and
collected by centrifugation in tubes, the pellets resuspended in
1 ml ice-cold buffer (containing 25 mM Hepes, pH 7.2, 250 mM
sucrose, 2 mM MgCl2 and a broad spectrum protease inhibitors
cocktail - Sigma), homogenized (4uC, 20 strokes, Teflon pestle-
glass Thomas type A homogenizer) followed by sonication
(3630 sec bursts) using a Branson sonicator. The homogenate
was fractionated as described above for the lung and kidney
membranes.
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MLEC-wt and MLEC-Cav1KO cells were grown to confluence
in quadruplicate in 15 cm Petri dishes. Freshly harvested lungs
and kidneys from WT, Cav1
2/2 and cavin-1
2/2 mice were used
for total RNA isolation. Total RNA was isolated using Trizol
(Invitrogen), as per manufacturer’s instructions.
Real-time quantitative PCR
RNA integrity and quality were determined using Bioanalyzer
(Agilent) and NanoDrop (Thermo-Fisher). One microgram of total
RNA was reverse transcribed using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). cDNA amplified from
10 ng RNA were used in triplicate for quantitative real-time PCR
using TaqmanH Gene Expression Assays (ABI) designed for mouse
PV1 (PV1/Plvap), Cav1, cavin-1 and Actin B (ActB) mRNA
detection and the TaqManH Gene Expression Master Mix, as per
manufacturer’s instructions. The PCR was performed on ABI
7500 Real Time PCR System with SDS software. The
comparative CT method (2
2DDCT) of relative quantitation was
used to compare the two genotypes.
PNGase treatment to remove N-linked glycans
Solubilized membrane (Mem) and cytosolic (Cyt) proteins
(100 mg) were treated with PNGase F (New England Biological),
as per manufacturer’s instructions. Controls were incubated in the
same conditions except that PNGase F was omitted. The samples
were resolved by 8% SDS-PAGe and the proteins transferred to
PVDF membrane and immunoblotted with chicken anti-PV1C
pAb.
35S metabolic labeling of MLEC
MLEC-wt and MLEC-Cav1KO cells were grown to confluence
in 60 mm dishes. Cells were Met and Cys starved by incubation
(2 h, 37uC) in
35S labeling medium consisting of EBM medium
lacking these Met and Cys (Lonza). 100 mCi of
35S Translabel
(Perkin-Elmer) consisting of a mix of
35S labeled Met and Cys were
added to the 35S labeling medium and the cells were incubated for
10 min at 37uC to allow for the
35S-labeled aminoacids to be
incorporated in proteins during translation. Mouse PV1 has 8
methionines and 10 cysteines in its primary sequence. After 2
washes in EBM2, the cells were chased for 0, 5 min, 15 min,
30 min or 1, 2, 4, 8, 12 and 24 h when the cells were rinsed in
PBS, collected by scrapping in 1 ml solubilization buffer [1%
Triton X-100 in 10 mM Tris-Cl, pH 7.4, 150 mM NaCl and
protease inhibitors cocktail (Sigma cat# P8340)] followed by
incubation (4uC, 2 h) with end over end rotation to complete the
solubilization, These conditions are known to efficiently solubilize
PV1 [8]. The samples were centrifuged (1 h, 4uC, 100,0006g) to
remove the insoluble material as a pellet. The supernatant,
containing the solubilized PV1, was added to 50 ml (settled gel) of
chicken anti-mouse PV1 directly coupled to AffiGel 10 beads, as
described before [8]. Beads coupled with preimmune chicken IgG
were used as controls. The samples were incubated (o/n, 4uC) by
rotation after which the beads were collected by centrifugation
(5 min, 4uC, 3006g) and washed 3 times at 4uC with solubilization
buffer. PV1 bound to the beads was solubilized in SDS-PAGE
sample buffer, resolved by 8% SDS-PAGE, the gel treated with
Amplify (GE Healthcare), vacuum dried and exposed to a
multipurpose standard (MS) phosphor storage screen (Kodak).
The signal was imaged using a Typhoon 9400 scanner (Molecular
Dynamics, GE Healthcare) and quantified using ImageJ or
GelEval v1.35 (FrogDance, UK) software. Data from three
separate experiments were used to obtain the degradation curves.
Flow Cytometry
Labeled cells were analyzed by either using a FacsCalibur or a
CANTO flow cytometer controlled by either CellQuest or DIVA
software, respectively (BD Biosciences). The data analysis was
carried out using FlowJo (Tree Star, Ashland, OR) software. Each
experiment had 4–8 samples per time point and was repeated at
least three times. Median fluorescence from at least 10,000 live
cells was calculated in each sample. Statistical significance was
calculated using Student’s t test.
Evaluation of cell surface PV1 levels by flow cytometry
Either MLEC-wt or MLEC-cav1KO cells were labeled live and
while adherent with 1.5 mg/ml MECA-32-Alexa 647 mAb for
30 min at 4uC in MLEC growth medium. The cells were rinsed
(36, RT) in PBS and non-enzymatically detached using EDTA
(Cell Dissociation Solution, Sigma). The cells were mixed with an
equal volume of 1% BSA in PBS, and kept on ice in the dark until
examined by flow cytometry.
Evaluation of PV1 internalization rate by flow cytometry
Prior to the experiment the MLEC-wt and MLEC-Cav1KO
cells were serum-starved (2 h, 37uC) in serum-free endothelial
basal medium 2 (EBM2) (Lonza), followed by labeling (30 min,
10uC) with fluorophore coupled rat anti-mouse PV1 MECA-32
mAb (1.5 mg/ml) in EBM2 supplemented with 2% BSA. After
washing (36, EBM2) the excess primary antibody off, the cells
were incubated with full MLEC growth medium at 37uC for the
indicated periods of time to allow for the internalization of the
antibody. To determine the internalized fraction, the cells were
washed once (30 s, RT) in acidic PBS, pH 2.5, once in neutral
PBS and detached by incubation (10 min, 37uC) in a mixture of
trypsin/EDTA (Lonza). The combination of acid wash and the
trypsin treatment were very effective in removing the surface anti-
PV1, demonstrated on separate control samples incubated at 4uC.
To determine the initial surface pool of PV1, cells were
incubated with fluorescent anti-PV1 as above, rinsed in neutral
PBS and non-enzymatically detached using EDTA (Cell Dissoci-
ation Solution, Sigma). These conditions do not disrupt the anti-
PV1 - PV1 interaction on cell surface.
The cell suspensions were mixed with an equal volume of 1%
BSA in PBS, and kept on ice in the dark until examined by flow
cytometry. The average median fluorescence was calculated from
each time point and the percentage of internalized PV1 was
calculated from the ratio of internalized/initial anti-PV1 signal.
Fluorescent rat IgG2a was used as isotype control for MECA-32
antibody.
Evaluation of PV1 degradation pathway
Equal numbers of MLEC-WT and MLEC-Cav1KO were
seeded into 6 cm dishes at 90% confluence the evening before and
cultured in full growth medium until the next day when the
medium was replaced with MLEC growth medium containing
either proteasome inhibitors (i.e. epoxomycin or clasto-Lactacystin
beta Lactone), lysosome inhibitors (i.e. leupeptin, E64-D or
bafilomycin A1) or DMSO vehicle. The cells were further
incubated for 4 h, 8 h or 24 h at 37uC in a cell culture incubator
with 5%CO2 atmosphere. The final inhibitor concentrations
obtained from 1000-fold concentrated stocks in DMSO were as
follows: 2 mM epoxomycin, 10 mM clasto-Lactacystin b-Lactone,
10 mM E-64D, 50 mM leupeptin, 1 mMo r1 0mM bafilomycin A1.
At the end of the experiment cells were rinsed (26, RT) in 5 ml
PBS and then solubilized (1 h, 4uC) in .5 ml RIPA buffer (1%
Triton X-100, 0.4% sodium deoxycholate, 0.1% sodium dodecyl
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inhibitors. The samples were centrifuged (1 h, 4uC, 100,0006g) to
remove the insoluble material as a pellet. The supernatant was
transferred to a fresh tube and used to determine the protein
concentration using the BCA assay and standards made in RIPA
buffer. Equal amounts (20 mg) of proteins from different samples
were resolved by 8% SDS-PAGE, transferred to PVDF mem-
branes and immunoblotted with either rat-anti-mouse PV1 mAb
MECA-32 or chicken anti-mouse PV1C pAb, as described
[10,11].
Evaluation of the effect of dynamin and clathrin
inhibitors on PV1 internalization
To determine the effects of clathrin mediated uptake inhibitor
PitStop2 [61] or the dynamin inhibitors Dynasore (10 and 80 mM)
[38] or Dyngo4a (30 mM) [36] on PV1 internalization, cells were
serum-starved (2 h, 37uC) in serum-free endothelial basal medium
2 (EBM2) (Lonza), followed by labeling (30 min, 10uC) with
Alexa647-MECA-32 mAb (1.5 mg/ml) in EBM2 supplemented
with either: 25 mM PitStop2 (Ascent Scientific), 25 mM PitStop2
negative control compound (Ascent Scientific), 10 mMo r8 0mM
dynasore (EMD Chemicals) or 30 mM Dyngo4a (Ascent Scientif-
ic). Negative controls consisted of cells not treated or treated with
DMSO vehicle (1 ml/ml medium). After washing (36, EBM2) the
excess primary antibody off, the cells were incubated (37uC,
15 min or 60 min) with either EMB2 or full MLEC growth
medium supplemented with inhibitors or vehicle. For each
inhibitor we have determined the total surface PV1 signal at
t0 min, t15 min and t60 min by nonenzymatic digestion as well as
the internalized fraction using the combination of acid wash and
trypsin/EDTA, as described above. For each inhibitor the samples
were run in quadruplicate in three separate experiments. Because
protein in the medium might inactivate the inhibitors, for each
inhibitor the assay was carried out in absence and presence of
protein in the medium (EBM2 vs. full growth MLEC medium).
Positive controls for each inhibitor effectiveness consisted of
Alexa647 labeled human transferrin or EGF (Invitrogen, Molec-
ular Probes). Serum starved (o/n, 37uC, EBM2+1%BSA)
endothelial cells were incubated (30 min, 10uC) in serum-free
medium supplemented with inhibitors and either 25 mg/ml
transferrin-F647 or 1 mg/ml biotinEGF-streptavidin-Alexa647,
the excess label washed away, the cells incubated (10 min, 37uC)
in growth medium with inhibitors to allow internalization of the
surface bound label, when the cells were acid washed, resuspended
using trypsin/EDTA and examined by flow cytometry.
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